Cellular therapy in Tuberculosis

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 32-38

  Parida, Shreemanta K ^a   Madansein, Rajhmun ^b,c,d   Singh, Nalini ^c,e   Padayatchi, Nesri ^d,e   Master, Iqbal ^c,e   Naidu, Kantharuben ^c,e   Zumla, Alimuddin ^f   Maeurer, Markus ^a,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Inkosi Albert Luthuli Hospital   (South Africa)

^c King Dinuzulu Hospital   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e MSC Durban Team ^*  (South Africa)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; HDT; Host directed therapy; Inflammation; M.tuberculosis; MDR TB; Mesenchymal stromal cells; T cells; Tuberculosis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR;

ADJUVANT THERAPY; ARTICLE; B LYMPHOCYTE; BONE MARROW DERIVED MONONUCLEAR CELL; CELL THERAPY; CLONAL ANERGY; DENDRITIC CELL; EXOSOME; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LYMPHOKINE ACTIVATED KILLER CELL; MESENCHYMAL STROMA CELL; MULTIDRUG RESISTANT TUBERCULOSIS; SALVAGE THERAPY; TISSUE INJURY; TUMOR ASSOCIATED LEUKOCYTE; CELL TRANSPLANTATION; IMMUNOLOGY; INFECTION; MESENCHYMAL STEM CELL TRANSPLANTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

CELL TRANSPLANTATION; HUMANS; INFECTION; MESENCHYMAL STEM CELL TRANSPLANTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84925262644     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.01.016     Document Type: Article

References (68)

1. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3(4):393-403.
2. Hogan B.L., Yingling J.M. Epithelial/mesenchymal interactions and branching morphogenesis of the lung. Curr Opin Genet Dev 1998, 8(4):481-486.
3. Sabatini F., Petecchia L., Tavian M., Jodon de Villeroche V., Rossi G.A., Brouty-Boye D. Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Lab Invest 2005, 85(8):962-971.
4. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822.
5. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466(7308):829-834.
6. Tropea K.A., Leder E., Aslam M., Lau A.N., Raiser D.M., Lee J.H., et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012, 302(9):L829-L837.
7. Islam M.N., Das S.R., Emin M.T., Wei M., Sun L., Westphalen K., et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012, 18(5):759-765.
8. Spees J.L., Olson S.D., Whitney M.J., Prockop D.J. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(5):1283-1288.
9. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4):315-317.
10. Lv F.J., Tuan R.S., Cheung K.M., Leung V.Y. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem cells 2014, 32(6):1408-1419.
11. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006, 119(Pt 11):2204-2213.
12. Lama V.N., Smith L., Badri L., Flint A., Andrei A.C., Murray S., et al. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest 2007, 117(4):989-996.
13. Ricciardi M., Malpeli G., Bifari F., Bassi G., Pacelli L., Nwabo Kamdje A.H., et al. Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow. PLoS One 2012, 7(5):e35639.
14. Sinclair K., Yerkovich S.T., Chambers D.C. Mesenchymal stem cells and the lung. Respirology 2013, 18(3):397-411.
15. Yagi H., Soto-Gutierrez A., Parekkadan B., Kitagawa Y., Tompkins R.G., Kobayashi N., et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010, 19(6):667-679.
16. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101(9):3722-3729.
17. Kavanagh H., Mahon B.P. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011, 66(4):523-531.
18. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57(11):1192-1203.
19. Duffy M.M., Ritter T., Ceredig R., Griffin M.D. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011, 2(4):34.
20. English K., Wood K.J. Immunogenicity of embryonic stem cell-derived progenitors after transplantation. Curr Opin Organ Transplant 2011, 16(1):90-95.
21. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75(3):389-397.
22. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007, 110(2):91-100.
23. Prockop D.J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem cells 2013, 31(10):2042-2046.
24. Mayer-Barber K.D., Andrade B.B., Oland S.D., Amaral E.P., Barber D.L., Gonzales J., et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511(7507):99-103.
25. Leijten J., Georgi N., Moreira Teixeira L., van Blitterswijk C.A., Post J.N., Karperien M. Metabolic programming of mesenchymal stromal cells by oxygen tension directs chondrogenic cell fate. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(38):13954-13959.
26. Spees J.L., Olson S.D., Ylostalo J., Lynch P.J., Smith J., Perry A., et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(5):2397-2402.
27. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010, 5(4):e10088.
28. Rane L., Rahman S., Magalhaes I., Ahmed R., Spangberg M., Kondova I., et al. Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue. Genes Immun 2011, 12(7):513-522.
29. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular therapy: the journal of the American Society of Gene Therapy 2012, 20(1):14-20.
30. Khatri M., Saif Y.M. Influenza virus infects bone marrow mesenchymal stromal cells in vitro: implications for bone marrow transplantation. Cell Transplant 2013, 22(3):461-468.
31. Kaipe H., Erkers T., Sadeghi B., Ringden O. Stromal cells-are they really useful for GVHD?. Bone Marrow Transplant 2014.
32. Pessina A., Bonomi A., Cocce V., Bernardo M.E., Cometa A.M., Ferrari M., et al. Assessment of human herpesvirus-6 infection in mesenchymal stromal cells ex vivo expanded for clinical use. Transpl Infect Dis 2009, 11(6):491-496.
33. Hall S.R., Tsoyi K., Ith B., Padera R.F., Lederer J.A., Wang Z., et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem cells 2013, 31(2):397-407.
34. Caplan A.I. Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217(2):318-324.
35. Matthay M.A., Goolaerts A., Howard J.P., Lee J.W. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 2010, 38(10 Suppl):S569-S573.
36. Mei S.H., McCarter S.D., Deng Y., Parker C.H., Liles W.C., Stewart D.J. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS medicine 2007, 4(9):e269.
37. Lalu M.M., McIntyre L., Pugliese C., Fergusson D., Winston B.W., Marshall J.C., et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012, 7(10):e47559.
38. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.T., Reagan M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013, 123(4):1542-1555.
39. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110(10):3499-3506.
40. Skrahin A., Ahmed R.K., Ferrara G., Rane L., Poiret T., Isaikina Y., et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. The Lancet Respiratory medicine 2014, 2(2):108-122.
41. Battiwalla M., Barrett A.J. Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. Tissue Eng Part B Rev 2014, 20(3):211-217.
42. Walter J., Ware L.B., Matthay M.A. Mesenchymal stem cells: mechanisms of potential therapeutic benefi t in ARDS and sepsis. Lancet Resp Med 2014.
43. Kaufmann S.H., Lange C., Rao M., Balaji K.N., Lotze M., Schito M., et al. Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. The Lancet Respiratory medicine 2014, 2(4):301-320.
44. Topalian S.L., Rosenberg S.A. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Acta haematologica 1987, 78(Suppl 1):75-76.
45. Clark J.W., Longo D.L. Adoptive therapies: quo vadis?. Pathology and immunopathology research 1988, 7(6):442-458.
46. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988, 319(25):1676-1680.
47. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990, 323(9):570-578.
48. Jensen M.C., Riddell S.R. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunological reviews 2014, 257(1):127-144.
49. Dotti G., Gottschalk S., Savoldo B., Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological reviews 2014, 257(1):107-126.
50. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31(1):71-75.
51. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007, 117(5):1195-1203.
52. Poschke I., Lovgren T., Adamson L., Nystrom M., Andersson E., Hansson J., et al. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer immunology, immunotherapy: CII 2014, 63(10):1061-1071.
53. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257(5067):238-241.
54. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333(16):1038-1044.
55. Gerdemann U., Katari U.L., Papadopoulou A., Keirnan J.M., Craddock J.A., Liu H., et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013, 21(11):2113-2121.
56. Papadopoulou A., Gerdemann U., Katari U.L., Tzannou I., Liu H., Martinez C., et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Science translational medicine 2014, 6(242):242ra83.
57. Ostendorf B.N., Jehn C.F., Vuong L.G., Nogai H., Hemmati P.G., Gebauer B., et al. Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report. SpringerPlus 2014, 3:278.
58. Jurado J.O., Alvarez I.B., Pasquinelli V., Martinez G.J., Quiroga M.F., Abbate E., et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008, 181(1):116-125.
59. Chodisetti S.B., Gowthaman U., Rai P.K., Vidyarthi A., Khan N., Agrewala J.N. Triggering Through Toll-like Receptor 2 Limits Chronically Stimulated T-helper Type 1 Cells From Undergoing Exhaustion. J Infect Dis 2014.
60. Maus M.V., Grupp S.A., Porter D.L., June C.H., Antibody-modified T. cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123(17):2625-2635.
61. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344(6184):641-645.
62. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
63. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465.
64. Scholler J., Brady T.L., Binder-Scholl G., Hwang W.T., Plesa G., Hege K.M., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science translational medicine 2012, 4(132):132ra53.
65. Mitsuyasu R.T., Anton P.A., Deeks S.G., Scadden D.T., Connick E., Downs M.T., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000, 96(3):785-793.
66. Deeks S.G., Wagner B., Anton P.A., Mitsuyasu R.T., Scadden D.T., Huang C., et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002, 5(6):788-797.
67. Uhlin M., Gertow J., Uzunel M., Okas M., Berglund S., Watz E., et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012, 55(8):1064-1073.
68. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer immunology, immunotherapy: CII 2010, 59(12):1781-1789.